Improved efficacy of α-particle-targeted radiation therapy: Dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72

Cancer

Volumn 116, Issue SUPPL. 4, 2010, Pages 1059-1066

  Milenic, Diane E ^a   Brady, Erik D ^a   Garmestani, Kayhan ^a   Albert, Paul S ^b   Abdulla, Alia ^a   Brechbiel, Martin W ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

particle; 213bi; Human epidermal growth factor 2; Humanized cc49 monoclonal antibody; Radioimmunotherapy; Trastuzumab; Tumor associated glycoprotein 72

Indexed keywords

BISMUTH 213; CYCLOHEXYL A'' PENTETIC ACID; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CC 49 BI 213; PENTETIC ACID DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ALPHA RADIATION; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER RADIOTHERAPY; COLON CARCINOMA; CONFERENCE PAPER; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; INJECTION; ISOTOPE LABELING; MOLECULE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PERITONEAL DISEASE; PERITONEUM TUMOR; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VOLUME; XENOGRAFT;

ALPHA PARTICLES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; COLONIC NEOPLASMS; FEMALE; GLYCOPROTEINS; HUMANS; MICE; MICE, NUDE; RADIOIMMUNOTHERAPY; RECEPTOR, ERBB-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 76249102432     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24793     Document Type: Conference Paper

References (40)

1. Brechbiel MW. Targeted alpha-therapy: past, present, future Dalton Trans. 2007;43:4918-4928.
2. Horak E, Hartmann F, Garmestani K, et al. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. J Nucl Med. 1997;38: 1944-1950.
3. Milenic DE, Garmestani K, Brady ED, et al. Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm. 2005;20:557-568.
4. 213Bi-labeled domain-deleted humanized monoclonal antibody. Cancer Biother Radiopharm. 2004;19:135-148.
5. Milenic DE, Garmestani K, Brady ED, et al. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res. 2004;10:7834-7841.
6. Blumenthal RD, Kashi R, Stephens R, Sharkey RM, Goldenberg DM. Improved radioimmunotherapy of colorectal cancer xenografts using antibody mixtures against carcinoembryonic antigen and colon-specific antigen-p. Cancer Immunol Immunother. 1991;32:203-310.
7. Buchsbaum DJ, Rogers BE, Khazaeli MB, et al. Targeting strategies for cancer radiotherapy. Clin Cancer Res. 1999;5 (10 suppl):3048s-3055s.
8. DeNardo GL, Tobin E, Chan K, Bradt BM, DeNardo SJ. Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies. Clin Cancer Res. 2005;11(19 pt 2):7075s-7079s.
9. Greiner JW, Guadagni F, Goldstein D, et al. Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. J Clin Oncol. 1992;10:735-746.
10. Guadagni F, Schlom J, Johnston WW, et al. Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells. J Natl Cancer Inst. 1989;81:502-512.
11. Meredith RF, Khazaeli MB, Plott WE, et al. Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Clin Cancer Res. 1996;2:1811-1818.
12. Milenic DE, Garmestani K, Brady ED, et al. Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease. Clin Cancer Res. 2007;13:1926-1935.
13. Milenic DE, Garmestani K, Brady ED, et al. Multimodality therapy: potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease. Clin Cancer Res. 2008;14:5108-5115.
14. Schlom J, Siler K, Milenic DE, et al. Monoclonal antibody-based therapy of a human tumor xenograft with a 177lutetiumlabeled immunoconjugate. Cancer Res. 1991; 51:2889-2896.
15. Siler K, Eggensperger D, Hand PH, et al. Therapeutic efficacy of a high-affinity anticarcinoembryonic antigen monoclonal antibody (COL-1). Biotechnol Ther. 1993;4:163-181.
16. Mattes MJ, Sharkey RM, Karacay H, Czuczman MS, Goldenberg DM. Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab). Clin Cancer Res. 2008;14:6154-6160.
17. Johnson VG, Schlom J, Paterson AJ, Bennett J, Magnani JL, Colcher D. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res. 1986;46:850-857.
18. Thor A, Ohuchi N, Szpak CA, Johnston WW, Schlom J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res. 1986;46:3118-3124.
19. Slavin-Chiorini DC, Kashmiri SV, Lee HS, et al. A CDR-grafted (humanized) domain-deleted antitumor antibody. Cancer Biother Radiopharm. 1997;12:305-316.
20. Agus DB, Bunn PA Jr, Franklin W, Garcia M, Ozols RF. HER-2/neu as a therapeutic target in nonsmall cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol. 2000;27(6 suppl 11):53-63.
21. Natali PG, Nicotra MR, Bigotti A, et al. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer. 1990;45:457-461.
22. Tom BH, Rutzky LH, Jakstys MH. Human colonic adenocarcinoma cells. Establishment and description of a new cell line. In Vitro. 1976;12:180-191.
23. Slavin-Chiorini DC, Kashmiri SV, Schlom J, et al. Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. Cancer Res. 1995;55(23 suppl):5957s-5967s.
24. Milenic DE, Garmestani K, Chappell LL, et al. In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. Nucl Med Biol. 2002;29:431-442.
25. Brechbiel MW, Gansow OA. Synthesis of C-functionalized trans-cyclohexyldiethylene-triamine-pentaacetic acids for labelling of monoclonal antibodies with the bismuth-212 aparticle emitter. J Chem Soc Perkin Trans 1. 1992:1173-1178.
26. 111In labeled Herceptin. Nucl Med Biol. 2002;29: 599-606.
27. Milenic DE, Roselli M, Mirzadeh S, et al. In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates. Cancer Biother Radiopharm. 2001;16:133-146.
28. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193:265-275.
29. Pippin CG, Parker TA, McMurry TJ, Brechbiel MW. Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. Bioconjug Chem. 1992;3:342-345.
30. Schott ME, Milenic DE, Yokota T, et al. Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single-chain Fv molecules. Cancer Res. 1992; 52:6413-6417.
31. Humm JL. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med. 1986;27:1490-1497.
32. Kurtzman SH, Russo A, Mitchell JB, et al. 212Bismuth linked to an antipancreatic carcinoma antibody: model for alpha-particle-emitter radioimmunotherapy. J Natl Cancer Inst. 1988;80:449-452.
33. Li Y, Abbas Rizvi SM, Blair nee Brown JM, et al. Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted alpha-therapy with 213Bi-conjugates. Int J Radiat Oncol Biol Phys. 2004;60:896-908.
34. Wang J, Abbas Rizvi SM, Madigan MC, et al. Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted alpha radioimmunoconjugates. Prostate. 2006; 66:1753-1767.
35. Gaffar SA, Pant KD, Shochat D, Bennett SJ, Goldenberg DM. Experimental studies of tumor radioimmunodetection using antibody mixtures against carcinoembryonic antigen (CEA) and colon-specific antigen-p (CSAp). Int J Cancer. 1981;27:101-105.
36. Munz DL, Alavi A, Koprowski H, Herlyn D. Enhancement of tumor contrast on radioimmunoscans by using mixtures of monoclonal antibody F(ab0)2 fragments. Nuklearmedizin. 1986;25:216-219.
37. Munz DL, Alavi A, Koprowski H, Herlyn D. Improved radioimmunoimaging of human tumor xenografts by a mixture of monoclonal antibody F(ab0)2 fragments. J Nucl Med. 1986;27:1739-1745.
38. Ohuchi N, Simpson JF, Colcher D, Schlom J. Complementation of anti-CEA and anti-TAG-72 monoclonal antibodies in reactivity to human gastric adenocarcinomas. Int J Cancer. 1987;40:726-733.
39. Chauhan SC, Vinayek N, Maher DM, et al. Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multitargeted antibody-guided therapy. J Histochem Cytochem. 2007;55:867-875.
40. Milenic DE, Wong KJ, Baidoo KE, et al. Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biother Radiopharm. 2008;23: 619-631.